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Abstract
Background It is important to gain insight into opportunities
for secondary prevention of cardiovascular disease. Our aim
was to investigate levels and trends in cardiovascular risk
factors and drug treatment in Dutch post-myocardial infarc-
tion (MI) patients between 2002 and 2006 and to make
comparisons with the EUROASPIRE surveys (1999–2007).
Methods We analysed data from 4837 post-MI patients
(aged 69 years, 78% men) from 32 Dutch hospitals, using
baseline cross-sectional data from the Alpha Omega Trial.
Results Between 2002 and 2006, significant declines were
found in the prevalence of smoking (23% to 16%, p<0.001),
hypercholesterolaemia (≥5 mmol/l; 54% to 27%, p<0.0001)
and hypertension (≥140/90 mmHg; 58% to 48%, p<0.001).
The prevalence of antithrombotic drugs was high (97%).
The prevalence of lipid-modifying drugs and antihyperten-
sives was high, and increased (74% to 90%, p<0.0001 and
82% to 93%, p<0.001, respectively). The prevalence of
obesity (27%) was high in 2002 and decreased to 24% in
2006, albeit not significantly. Diabetes prevalence was high
and increased between 2002 and 2006 (18% to 22%, p0
0.02). In comparison with EUROASPIRE patients, who
were on average 8–10 years younger, our study in 2006
included patients with lower levels of obesity, hypertension,
hypercholesterolaemia, diabetes and lower use of antiplate-
lets and β-blockers, but similar levels of lipid-modifying
drugs.
Conclusions This study showed that older Dutch post-MI
patients were adequately treated with drugs, and that risk
factors reached lower levels than in the younger EURO-
ASPIRE patients. However, there is room for improvement
in diet and lifestyle, given the high prevalence of smoking,
obesity, and diabetes.
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Cardiovascular diseases (CVD) claim over 4 million lives in
Europe every year [1, 2]. In the Netherlands, CVD caused
346,000 hospitalisations and accounted for 30% of total
mortality in 2008 [3]. Although mortality due to CVD is
declining in most European countries, the number of CVD
patients is still increasing [3–5]. The decline in mortality
could be due to improved prognosis and better management
of CVD [3, 4]. The increasing prevalence of CVD is due to
ageing populations and improved survival of patients with
CVD [3, 4]. It is unknown how trends in risk factors and
drug treatment have recently evolved over time in the Neth-
erlands, especially in older patients with coronary heart
disease (CHD) (mean age 69 years), and how these compare
with other European countries.
The largest study in Europe examining trends in risk
factors and drug treatment in CHD patients is the EURO-
ASPIRE study. Independent cross-sectional surveys were
carried out in eight European countries in 2975 CHD
patients (1999–2000, mean age 59 years) and in 2392
CHD patients (2006–2007, mean age 61 years) [6]. In
2007, the prevalence for smoking was 18%, for obesity
38%, for elevated blood pressure (BP ≥140/90 mmHg)
61%, for hypercholesterolaemia 46% and for self-reported
diabetes mellitus 28%. Compared with 1999, obesity and
diabetes had increased (both by 6%) and hypercholester-
olaemia had decreased (by 32%), whereas smoking and
elevated BP remained stable. On the basis of EUROAS-
PIRE it was recommended that more effective lifestyle
interventions were needed for CHD patients, i.e. smoking
cessation, weight loss and prevention of diabetes [6].
EUROASPIRE included only 387 Dutch CHD patients
and conclusions specific to this population could therefore
not be drawn [6].
From a clinical perspective it is important to gain
insight into opportunities for secondary prevention of
CVD. Therefore, we assessed time trends and levels of
CVD risk factors and drug treatment in 4837 post-
myocardial infarction (MI) patients in the Netherlands
between 2002 and 2006. A second aim was to compare
these time trends and levels with those in EUROASPIRE
in the period 1999–2007.
Methods
Study design and population
We used baseline cross-sectional data of the Alpha Ome-
ga Trial (ClinicalTrials.gov identifier: NCT00127452, see
website http://www.alphaomegatrial.com), a multi-centre
trial of n-3 fatty acids and CVD endpoints [7, 8]. The
study involved 4837 Dutch men and women aged 60–
80 years with a documented history of MI who were
recruited from 32 Dutch hospitals between April 2002 and
December 2006. Written informed consent was obtained
from each subject. The study was conducted in accordance
with the Helsinki Declaration and approved by the central
Medical Ethics Committee South-West Holland and by the
local medical ethics committees of participating hospitals
(see online supplementary material under participating
cardiology centres).
Measurements
Patients were physically examined by trained research
nurses in the hospital or at home, according to a standard
protocol [7]. Information was obtained on current health
status, medical history, lifestyle and drug treatment.
Weight and height were measured once with patients
wearing light clothes and no shoes. Body mass index
(BMI) was calculated as weight (kg)/height
2 (m). Obesity
was defined as BMI ≥30.0 kg/m
2, and morbid obesity as
BMI ≥40.0 kg/m
2. Waist circumference was measured at the
midpoint between the bottom rib and the top of the hipbone.
Central obesity was defined as a waist circumference of
≥88 cm in women or ≥102 cm in men [9]. Systolic and
diastolic BP (1st and 5th Korotkoff sounds, respectively)
were measured twice at the left upper arm after a 10-min
seated rest with an automated device (Omron HEM-711,
Omron Healthcare Europe B.V., Hoofddorp, NL). Values
were averaged. Elevated BP levels (or hypertension, as in
EUROASPIRE [6]) were defined as systolic BP ≥140 mmHg
and/or diastolic BP ≥90 mmHg.
Casual venous blood samples were taken for the assess-
ment of serum lipids and plasma glucose as described in
detail previously [7]. Serum total cholesterol, high-density
lipoprotein cholesterol (HDL-c), triglycerides and glucose
were analysed by standard kits using an autoanalyser (Hita-
chi 912, Roche Diagnostics, Basel, Switzerland). Low-
density lipoprotein cholesterol (LDL-c) was calculated us-
ing the Friedewald formula [10]. Elevated cholesterol (or
hypercholesterolaemia, as in EUROASPIRE [6]) was de-
fined as total serum cholesterol ≥5.0 mmol/l (193 mg/dl).
Patients filled out questionnaires on smoking status (cur-
rent, former or never), educational level, drug treatment,
dietary advice prescribed by the physician, and history of
CVD, hypercholesterolaemia, hypertension and diabetes
mellitus. All of these were checked and completed, if need-
ed, by research nurses. Diabetes was defined as self-reported
physician diagnosis, drug treatment or glucose ≥7.0 mmol/
l (126 mg/dl) for fasting and ≥11.1 mmol/l (200 mg/dl) for
non-fasting patients. Self-reported diabetes was presented to
compare with EUROASPIRE. The majority of the diabetes
cases (73%) were based on a combination of these criteria
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cose values or drug treatment. Self-reported drug treat-
ment of the participants was coded by a pharmaco-
epidemiologist according to the Anatomical Therapeutic
Chemical Classification System (ATC) [11]. ATC codes
were C02, C03, C07, C08, and C09 for antihypertensive
drugs, C10 for lipid-modifying drug treatment (with
C10AA coding for statins and C10B coding for combi-
nations of statins with other lipid-modifying drugs), A10
for antidiabetic drug treatment and B01 for antithrom-
botic drug treatment.
Statistical analysis
To assess trends over time in CVD risk factors and drug
treatment use, we categorised patients according to enrol-
ment year. General linear models (GLM) were used to
estimate mean changes for continuous variables and per-
centage changes for dichotomous variables between 2002
and 2006, all adjusted for year, age and gender by entering
these as covariates in the GLM models. Tukey’s method was
used to estimate percentage or mean differences from 2006
to 2002 [12].
We compared our data with those from the EUROAS-
PIRE II (1999/2000) and III surveys (2006/2007) [6]. In
EUROASPIRE, changes over time in risk factors and drug
treatment had been adjusted using the same GLM and
Tukey’s method with survey, age and diagnostic category
as the main covariates [6].
P for trend was calculated with age- and gender-adjusted
linear (for continuous variables) or logistic (for binary var-
iables) regression models with year as the independent
variable. We also analysed CVD risk factors and drug treat-
ment by gender. P-values for interaction were calculated
from the linear regression models (term gender*year) and
p-values <0.2 were considered indicative for interaction.
For all other analyses, two-sided p-values <0.01 indicat-
ed statistical significance. SAS version 9.1 (SAS Institute,
Cary, North Carolina, USA) was used for all statistical
analyses.
Results
Patients entering the Alpha Omega Trial were on average
69.0 [SD 5.6] years and 78% were male. The prevalence of
central obesity (based on waist circumference) was 60%, the
prevalence of obesity (based on BMI) was 24% and for
morbid obesity it was 0.8%. Most patients were included
in 2005 and 2006 (60%). Characteristics of the study pop-
ulation by the year of enrolment are described in Table 1.
Time since MI at enrolment decreased from 5.6 [SD 3.9]
years in 2002 to 3.7 [SD 3.0] years in 2006.
CVD risk factors
TheAlphaOmegaTrialshowedsignificantdeclines(p<0.001)
in lipid levels between 2002 and 2006 (Table 1), i.e.
−0.67 mmol/l (26 mg/dl) in serum total cholesterol,
−0.72 mmol/l (28 mg/dl) in LDL-c and systolic and diastolic
BP levels (−4.5 and −3.9 mmHg, respectively, p<0.001).
Elevated cholesterol (54% to 27%, p<0.0001), elevated BP
levels (58% to 48%, p<0.0001), and current smoking (23% to
16%, p00.0003) also decreased. The prevalence of obesity
(27%) and central obesity (59%) started at high levels in 2002,
but decreased slightly or remained constant, respectively, over
the total time period. Approximately 12% were receiving
dietary advice from the physician. The prevalence of diabetes
was high (18%) and increased to 22% (p00.02).
Drug treatment
Drug treatment started at high levels in 2002 (Table 2).
Antithrombotic drugs were prescribed to 97% of the patients
in 2002 and this remained constant throughout the years.
Increases were found for lipid-modifying drugs (74% to
90%, p<0.0001) and antihypertensives (82% to 93%, p<
0.0001). Of the lipid-modifying drugs, 98% consisted of
statins in the Alpha Omega Trial. Among the antihyperten-
sive drugs, the largest increase between 2002 and 2006 was
found for β-blockers (+21%) and angiotensin II receptor
blockers (+9%). Antidiabetic treatment started at 12% in
2002 and increased to 16% in 2006. The increase was
mainly due to biguanides (metformin) (+4.8%) and insulin
(+3.6%).
Differences between men and women
Men (n03783) and women (n01054) had similar levels of
risk factors and drug treatment in 2002, except for elevated
cholesterol which was higher in women than in men (63%
vs. 50%, p00.01). The number of patients with elevated
cholesterol was halved in 2006 in both men and women, but
remained higher in women than in men (33% vs. 25%, p0
0.008), despite similar prescription rates for lipid-modifying
drugs in men and women (in 2006; 90% and 87% respec-
tively). Systolic BP levels in 2006 were significantly higher
in women (mean 140.6 [SD 23.6] mmHg) than in men
(mean 138.7 [SD 21.5] mmHg, p00.04), but antihyperten-
sive prescription rates in 2006 were similar (93%).
Trends in risk factors and medication between 2002 and
2006 were generally similar in men and women.
Comparison with EUROASPIRE
EUROASPIRE patients were 8–10 years younger (59 and
61 years in survey II and III, respectively) than our patients
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and 77% men, respectively, in the EUROASPIRE surveys)
compared with 78% in the Alpha Omega Trial (Table 3).
Besides post-MI patients, the EUROASPIRE study popula-
tion also consisted of patients who underwent PCI, and
patients who had angina pectoris or acute coronary syn-
drome [6]. We found similar initial risk factor levels com-
paring the Alpha Omega Trial (2002) to EUROASPIRE II
(1999–2000) data, except for a lower prevalence of elevated
cholesterol, self-reported diabetes and β-blocker use. We also
Table 1 Study characteristics and CVD risk factors of 4837 post-MI patients included in the Alpha Omega Trial between 2002 and 2006 by year of
enrolment
2002 2003 2004 2005 2006 P for trend
N 522 759 674 1398 1484
Age (years) 69.4 (5.5) 69.3 (5.6) 69.3 (5.6) 68.6 (5.2) 69.0 (5.8)
Men%(n) 76 (395) 76 (577) 79 (532) 80 (1124) 78 (1155)
High education% (n) 10 (50) 12 (93) 11 (73) 13 (185) 13 (196)
Time since MI (years) 5.6 (3.9) 4.8 (3.1) 4.1 (2.7) 4.2 (3.1) 3.7 (3.0)
Prescribed diet% (n) 12 (61) 14 (102) 11 (71) 10 (145) 13 (186)
Cardiovascular risk factors
Current smoking% (n) 23 (121) 17 (131) 18 (121) 15 (208) 16 (231) <0.001
a
BMI (kg/m
2) 27.9 (3.9) 28.1 (3.9) 27.8 (3.9) 27.6 (3.7) 27.7 (3.9) 0.041
Obesity%(n) 27 (141) 26 (198) 23 (153) 23 (326) 24 (352) 0.08
Waist circumference (cm) 101.4 (10.5) 101.3 (10.5) 101.8 (10.3) 102.0 (10.3) 102.5 (10.8) 0.0096
a
Central obesity% (n) 59 (308) 58 (442) 60 (407) 59 (828) 60 (893) 0.28
Glucose (mmol/l) 6.07 (2.06) 6.16 (1.99) 6.29 (2.27) 5.98 (2.07) 6.47 (2.08) 0.001
a
Diabetes patients% (n) 18 (94) 21 (158) 24 (165) 19 (267) 22 (330) 0.19
Self-reported stroke% (n) 7 (36) 9 (67) 7 (46) 6 (83) 8 (113) 0.86
Total cholesterol (mmol/l) 5.18 (1.05) 5.09 (0.92) 4.81 (0.92) 4.54 (0.91) 4.51 (0.93) <0.001
a
Elevated cholesterol% (n) 54 (275) 50 (372) 35 (233) 27 (358) 27 (389) <0.001
a
LDL-c (mmol/l) 3.03 (0.91) 2.91 (0.80) 2.72 (0.78) 2.47 (0.77) 2.31 (0.77) <0.001
a
HDL-c (mmol/l) 1.27 (0.34) 1.30 (0.35) 1.23 (0.33) 1.24 (0.33) 1.36 (0.34) <0.001
a
Triglycerides (mmol/l)# 1.69 (1.28, 2.37) 1.70 (1.27, 2.38) 1.67 (1.21, 2.31) 1.62 (1.20, 2.28) 1.61 (1.18, 2.31) 0.002
a
Systolic BP (mmHg) 143.8 (21.6) 145.7 (21.9) 142.8 (21.1) 140.7 (21.0) 139.1 (22.0) <0.001
a
Diastolic BP (mmHg) 81.8 (11.3) 82.2 (11.2) 80.8 (10.6) 80.3 (10.8) 78.1 (11.5) <0.001
a
Elevated BP% (n) 58 (303) 62 (474) 55 (372) 50 (699) 48 (710) <0.001
a
Values represent mean (SD) # median (IQR), or percentage (n). P for trend is calculated with age- and gender-adjusted linear (for continuous
variables) or logistic (for binary variables) regression models with time in years as the independent variable
LDL-c low density lipoprotein cholesterol
HDL-c high density lipoprotein cholesterol
BP blood pressure
IQR interquartile range, percentiles p25–p75
SD standard deviation
BMI body mass index
To convert the values for glucose to milligrams per decilitre, divide by 0.05551
To convert the values for cholesterol to milligrams per decilitre, divide by 0.02586
To convert the values for triglycerides to milligrams per decilitre, divide by 0.01129
Diabetes was defined on basis of self-reported physician diagnosis, the use of antidiabetic drugs, or newly diagnosed diabetes (fasting glucose
≥7.0 mmol/l or non-fasting ≥11.1 mmol/l)
Obesity was defined as BMI ≥30 kg/m
2
Central obesity was defined as a waist circumference of ≥88 cm in women or ≥102 cm in men
Elevated cholesterol was defined as serum total cholesterol ≥5.0 mmol/l
Elevated BP was defined as systolic/diastolic BP ≥140/90 mmHg
aStatistically significant trend over time if p<0.01
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drugs in the Alpha Omega Trial (2002) compared with
EUROASPIRE II (1999–2000; 74% vs. 63%).
Achieved levels and trends were compared between 2002
and 2006 in the Alpha Omega Trial versus a longer period
(1999–2007) in EUROASPIRE. In the Alpha Omega Trial,
we observed significant age- and gender-adjusted declines
for smoking, elevated BP and elevated cholesterol and
significant increases in the prevalence of self-reported dia-
betes, lipid-modifying drugs, antihypertensives and β-
blockers. Obesity tended to decline in our study, although
not significantly. In EUROASPIRE, non-significant
declines were found for smoking, and non-significant
increases in obesity and hypertension rates. Significant
declines were demonstrated in EUROASPIRE for hyper-
cholesterolaemia and significant increases in the prevalence
Table 2 Prescribed cardiovas-
cular drugs of 4837 post-MI
patients included in the Alpha
Omega Trial between 2002 and
2006 by year of enrolment
ACEI angiotensin-converting
enzyme inhibitor; ARB angio-
tensin II receptor blocker
aStatistically significant trend
over time, p<0.01
P for trend is calculated with
age- and gender adjusted logistic
(for binary variables) regression
models with year as the indepen-
dent variable
2002 2003 2004 2005 2006 P for trend
Number of patients 522 759 674 1398 1484
Antiplatelet 81 (424) 82 (621) 84 (564) 85 (1186) 85 (1255) 0.035
Antithrombotics 97 (507) 96 (728) 98 (661) 98 (1369) 98 (1453) 0.035
β-blockers 54 (281) 62 (472) 71 (481) 71 (995) 75 (1114) <0.001
a
ACE inhibitors 40 (211) 40 (305) 39 (263) 47 (656) 43 (631) 0.043
ARBs 9 (48) 13 (102) 15 (101) 14 (198) 18 (265) <0.001
a
ACEIs and ARBs 49 (257) 53 (403) 53 (354) 60 (834) 59 (878) <0.001
a
CCBs 17 (89) 19 (143) 26 (172) 20 (283) 19 (280) 0.72
Diuretics 30 (155) 24 (182) 24 (160) 21 (299) 26 (388) 0.58
All antihypertensive drugs 82 (430) 85 (647) 90 (607) 91 (1271) 93 (1385) <0.001
a
All lipid-modifying drugs 74 (384) 81 (616) 87 (586) 89 (1244) 90 (1331) <0.001
a
Insulin 2 (13) 5 (36) 7 (44) 7 (91) 6 (89) 0.004
a
Biguanides 5 (24) 8 (62) 9 (60) 8 (118) 9 (139) 0.005
a
Sulphonamides 9 (49) 8 (64) 9 (58) 7 (91) 7 (99) 0.016
All antidiabetic drugs 12 (61) 15 (116) 18 (121) 15 (206) 16 (236) 0.11
Table 3 CVD risk factor and drug prescription levels and changes over time in post-MI patients, comparison of Alpha Omega Trial (AOT) and
EUROASPIRE using similar definitions
AOT AOT AOT EUROASPIRE EUROASPIRE EUROASPIRE
2002 2006 Change from 2002
to 2006
1999–2000 2006–2007 Change from 1999
to 2007
N0522 N01484 N01484 N02975 N02392 N02392
Age 69.4 (5.5) 69.0 (5.8) 59.4 (8.5) 60.9 (7.6)
Male gender 76% (395/522) 78% (1155/1484) 75% (2223/2975) 77% (1831/2392)
Current smoking 23% (121/522) 16% (231/1483) −7.9% (−12.4, −3.4)
a 21% (631/2971) 18% (434/2381) −1.6% (−5.3, 2.2)
Obesity 27% (141/520) 24% (352/1481) −3.3% (−8.4, 1.9) 33% (967/2963) 38% (902/2376) 5.5% (−0.1, 11.1)
Elevated BP 58% (303/521) 48% (710/1482) −10.0% (−16.0, −4.0)
a 58% (1730/2969) 61% (1452/2385) 3.4% (−3.2, 9.9)
Elevated
cholesterol
54% (275/514) 27% (389/1438) −26.3% (−32.0, −20.6)
a 77% (2122/2766) 46% (1049/2273) −32.4% (−39.0, −25.9)
a
Self-reported
diabetes mellitus
14% (74/519) 19% (274/1466) 4.7% (0.07, 9.3)
a 20% (598/2970) 28% (664/2371) 6.4% (1.4, 11.4)
a
Antiplatelet drugs% 81% (424/522) 85% (1255/1484) 3.1% (−1.4, 7.6) 84% (2486/2973) 93% (2214/2376) 7.1% (4.0, 10.2)
a
Lipid-modifying
drugs%
74% (384/522) 90% (1331/1484) 15.8% (11.7, 20.0)
a 63% (1864/2973) 89% (2110/2376) 23.7% (19.2, 28.1)
a
β-blockers% 54% (281/522) 75% (1114/1484) 21.2% (15.6, 26.8)
a 69% (2052/2973) 86% (2031/2376) 15.1% (8.5, 21.6)
a
Antihypertensives% 82% (430/522) 93% (1385/1484) 11.1% (7.4, 14.8)
a 91% (2694/2973) 97% (2301/2376) 5.5% (2.4, 8.5)
a
EUROASPIRE data were adapted from Lancet 2009: 373:929 by K. Kotseva [6]
aStatistically significant if confidence interval does not include zero
BP blood pressure
Changes were indicated as mean or percentage changes (95% CI) from age- and gender adjusted linear regression models
106 Neth Heart J (2012) 20:102–109of self-reported diabetes, antiplatelets, lipid-modifying
drugs, antihypertensives and β-blockers. Achieved levels
by 2006–2007 were similar in both studies for smoking
and lipid-modifying drugs. The achieved prevalence of obe-
sity, diabetes, elevated BP and elevated cholesterol was
lower in our study than in EUROASPIRE. The achieved
prescription rates of antiplatelets and β-blockers and to a
lesser extent antihypertensives were lower in our study than
in EUROASPIRE.
Discussion
In this large Dutch population of post-MI patients, we found
high drug prescription levels, in particular for antithrom-
botics, lipid-modifying drugs and antihypertensives. Over a
4-year period (2002–2006), increases in the use of lipid-
modifying drugs and antihypertensives corresponded with
declines in serum cholesterol (LDL) and BP levels. Smok-
ing prevalence decreased over time, whereas (central) obe-
sity remained relatively stable and the prevalence of
diabetes increased. In comparison with the on average
10 year younger EUROASPIRE patients, lower levels of
obesity, elevated BP, elevated cholesterol and diabetes, and
lower prescription rates of antiplatelets and β-blockers,
were observed in the Alpha Omega Trial in 2006. The
prevalence of smoking and lipid-modifying drugs, however,
were similar in the two studies [6].
A strength of the present study is the large sample size in
stable post-MI patients in the Netherlands. A limitation is that
our populationisnot a randomsampleofallMIpatientsinthe
Netherlands, because it includes only patients who were wil-
ling to participate in a 40-month trial [13]. Data on drug
prescriptions and smoking behaviour have the well-known
limitations of self-reporting. To limit this potential bias we
used a standard protocol and calibrated devices for risk factor
measurements and all questionnaires were checked by trained
research nurses and prescribed medication was classified by
an independent pharmaco-epidemiologist according to the
WHO ATC coding system.
We compared the baseline data of the Alpha Omega Trial
with those of EUROASPIRE, the largest study in Europe in
CHD patients, using similar definitions. However this com-
parison needs to be interpreted carefully, because EURO-
ASPIRE patients differ from those in the Alpha Omega Trial
in terms of age, duration of follow-up and type of CHD
patients (not only MI patients). A limitation to our study is
that we used baseline cross-sectional data from the Alpha
Omega Trial and not longitudinal data on the same patients.
Advantages are that these can be viewed as cross-sectional
surveys as in EUROASPIRE and eligible for estimating
trends over a reasonable time period.
Hypercholesterolaemia
Between 2002 and 2006, we showed a decreasing trend in
serum cholesterol (LDL) level and an increase in the use of
lipid-modifying drugs. In 2006, the prevalence of hyper-
cholesterolaemia was lower than in EUROASPIRE, possi-
bly due to a higher use of lipid-modifying drugs, for which
the effect in secondary prevention of CHD in elderly
patients (aged 65–80 years) has been established [14].
The Netherlands (33%) together with Finland (28%) had
the lowest prevalence of hypercholesterolaemia in EURO-
ASPIRE in 2006–2007. In descending order the prevalence
was 57% for Hungary, 49% for Germany and Italy, 47% for
Czech Republic, 42% for Slovenia and 41% for France [6].
These results together with our steep decreases in serum
cholesterol levels and increases in lipid-modifying drug use
suggest that serum cholesterol levels are well controlled in
Dutch patients.
Hypertension
We showed a decreasing trend in average systolic and dia-
stolic BP (−4 mmHg, p for trend <0.001). The 10% signif-
icant increase in antihypertensive drugs coincided with a
significant decline in elevated BP levels. Starting at a similar
rate of elevated BP as in EUROASPIRE, the prevalence of
elevated BP reached lower levels in the Alpha Omega Trial
than in EUROASPIRE (48% vs. 61%). The EUROASPIRE
surveys showed that the prevalence of hypertension
remained stable from 1999 to 2007, despite increases in
the use of all antihypertensives (except for calcium antago-
nists) [6]. Country-specific analyses in EUROASPIRE
showed that in some countries (Czech Republic, Finland,
Hungary, Italy, the Netherlands) the prevalence of hyperten-
sion increased over time whereas in other countries (i.e.
France, Germany, and Slovenia) the rates decreased [6].
At a drug-specific level, the use of β-blockers increased
in our cohort (21%), but was still lower than in EURO-
ASPIRE (75% vs. 85%) in 2006 [6]. In EUROASPIRE,
increases in the use of ACE inhibitors and angiotensin-II
receptor blockers and diuretics and a decrease in the use of
calcium channel blockers were reported. The trends for
these drugs were comparable with those in our study.
Insummary,between2002and2006antihypertensivedrug
use increased strongly in the Netherlands, but the use of β-
blockers was still lower than in other European countries.
Smoking
Smoking rates declined more strongly (from 23% to 16%)
over a shorter time period in the Alpha Omega Trial than in
EUROASPIRE (from 21% to 18%). At a country-specific
level, a similar prevalence of smoking was reported for the
Neth Heart J (2012) 20:102–109 107Dutch patients in EUROASPIRE III (15%). The prevalence
of smoking in the Netherlands was lower compared with
other European countries, with the highest prevalence in
France in 2007, i.e. 25% [6]. In spite of the relatively low
percentage of smokers among post-MI patients in the Neth-
erlands, there is still substantial health gain to be obtained
by further refraining from smoking.
Obesity and diabetes
The prevalence of obesity (27%) was high in 2002 in our
study and did not change over the years. In EUROASPIRE,
obesity rates started higher (33% in 1999) and increased
further to 38% in 2007 [6]. The highest obesity rates were
reported in 2006–2007 in Hungary (49%) and Germany
(43%), with the Netherlands (27%) and Finland (26%) hav-
ing the lowest prevalence [6]. Using waist circumference
cut-off points, we found a high prevalence of central obesity
in 2002 (59%), which remained stable over the years.
The prevalence of self-reported diabetes did increase over
the study period from 14% to 19%. At a country-specific
level, the Netherlands had the lowest reported prevalence of
diabetes in all EUROASPIRE survey years (13% in 1999
and 21% in 2007), whereas Hungary had the highest prev-
alence (45%) in 2007 [6].
These results suggest that even in the Netherlands with
one of the lowest prevalences of obesity and diabetes, cen-
tral obesity is still highly prevalent. As obesity and physical
inactivity are the main risk factors for diabetes [15], a
healthy diet and lifestyle is needed to reduce the high
absolute mortality risk of obese and diabetic post-MI
patients.
Importance of healthy diet and lifestyle in secondary
prevention of CVD
Lifestyle and dietary recommendations for secondary pre-
vention of CVD are: to stop smoking, to increase physical
activity and to eat healthily [16]. A healthy diet includes a
wide variety of foods and recommendations to reduce satu-
rated and trans fat and salt intake and encourage fruits and
vegetables, wholegrain cereals and bread, (oily) fish, lean
meat, and low-fat dairy products [16, 17]. A review on the
effect of lifestyle measures on all-cause mortality rates
showed that increased physical activity reduced all-cause
mortality by 25% in CHD patients [17]. For dietary inter-
ventions, a recent meta-analysis demonstrated that each 5%
increment in polyunsaturated fatty acid consumption re-
duced CHD risk by 10% in secondary prevention popula-
tions [18]. A meta-analysis of trials in CHD patients adding
1–2 grams of n-3 fatty acids per day reduced CHD mortality
by 20% [19]. This emphasises the importance of lifestyle
and dietary interventions in post-MI patients to lower their
absolute risk even further than with drug treatment alone.
Conclusions
This large population of post-MI patients in the Netherlands
is treated well pharmacologically. Moreover, both CVD risk
factors and drug prescription rates showed improvements
over a 4-year period. Until now, lifestyle interventions in
post-MI patients have received little attention as evident
from the high proportion of patients with obesity and dia-
betes and the steep increase in diabetes prevalence. In spite
of the relatively favourable risk factor and drug use levels in
post-MI patients in the Netherlands compared with other
European countries, further improvements of lifestyle and
dietary habits will improve the prognosis of these patients.
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